HRP20120262T1 - Farmaceutske formulacije i postupci za liječenje infekcija dišnih puteva - Google Patents

Farmaceutske formulacije i postupci za liječenje infekcija dišnih puteva Download PDF

Info

Publication number
HRP20120262T1
HRP20120262T1 HR20120262T HRP20120262T HRP20120262T1 HR P20120262 T1 HRP20120262 T1 HR P20120262T1 HR 20120262 T HR20120262 T HR 20120262T HR P20120262 T HRP20120262 T HR P20120262T HR P20120262 T1 HRP20120262 T1 HR P20120262T1
Authority
HR
Croatia
Prior art keywords
mol
sodium
calcium
pharmaceutical formulation
formulation according
Prior art date
Application number
HR20120262T
Other languages
English (en)
Inventor
M. Lipp Michael
W. Clarke Robert
L. Hava David
Batycky Richard
Hanrahan John
Original Assignee
Pulmatrix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pulmatrix filed Critical Pulmatrix
Publication of HRP20120262T1 publication Critical patent/HRP20120262T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Farmaceutska formulacija koja sadrži kalcijevu sol i natrijevu sol, naznačena time da je omjer Ca+2 prema Na+ od 4:1 (mol:mol) do 16:1 (mol:mol). Patent sadrži još 23 patentna zahtjeva.

Claims (24)

1. Farmaceutska formulacija koja sadrži kalcijevu sol i natrijevu sol, naznačena time da je omjer Ca+2 prema Na+ od 4:1 (mol:mol) do 16:1 (mol:mol).
2. Farmaceutska formulacija prema zahtjevu 1, naznačena time da omjer Ca+2 prema Na+ je od 4:1 (mol:mol) do 12:1 (mol:mol), 4:1 (mol:mol) do 10:1 (mol:mol), ili 4: 1 (mol:mol) do 8:1 (mol:mol).
3. Farmaceutska formulacija prema zahtjevu 1, naznačena time da omjer Ca+2 prema Na- je od 4:1 (mol:mol) do 7:1 (mol:mol), ili 4:1 (mol:mol) do 6:1 (mol:mol).
4. Farmaceutska formulacija prema zahtjevu 1, naznačena time da omjer Ca+2 prema Na+ je 4:1 (mol:mol), ili 4.5:1 (mol:mol), ili 5:1 (mol:mol), ili 5.5:1 (mol:mol) ili 6:1 (mol:mol).
5. Farmaceutska formulacija prema zahtjevu 1, naznačena time da omjer Ca+2 prema Na+ je 7:1 (mol:mol), 8:1 (mol:mol), 9:1(mol:mol); 10:1 (mol:mol), 11:1 (mol:mol) ili 12:1 (mol:mol).
6. Farmaceutska formulacija prema zahtjevu 1, naznačena time da omjer Ca+2 prema Na+ je 13:1 (mol:mol), 14:1 (mol:mol), 15:1 (mol:mol) ili 16:1 (mol:mol).
7. Farmaceutska formulacija prema bilo kojem od zahtjeva 1-6, naznačena time da farmaceutska formulacija je tekuća formulacija, pri čemu proizvoljno je Ca2+ ion prisutan u koncentraciji od 0.115 M do 1.15 M, ili pri čemu je Ca2+ ion prisutan u koncentraciji od 0.575 M do 1.15 M.
8. Farmaceutska formulacija prema zahtjevu 7, naznačena time da je Na+ ion prisutan u koncentraciji od 0.053 M do 0.3 M, ili pri čemu je Na+ ion prisutan u koncentraciji od 0.075 M do 0.3 M.
9. Farmaceutska formulacija prema zahtjevu 7 ili 8, naznačena time da je kalcijeva sol odabrana iz skupine koja sadrži kalcijev klorid, kalcijev karbonat, kalcijev acetat, kalcijev fosfat, kalcijev alginat; kalcijev stearat, kalcijev sorbat, kalcijev sulfat, kalcijev glukonat, kalcijev laktat i kalcijev citrat, pri čemu proizvoljno kalcijeva sol je kalcijev laktat, kalcijev citrat, ili kalcijev sulfat, ili pri čemu kalcijeva sol je kalcijev klorid ili kalcijev laktat.
10. Farmaceutska formulacija prema bilo kojem od zahtjeva 7-9, naznačena time da natrijeva sol je odabrana iz skupine koja sadrži natrijev klorid, natrijev acetat, natrijev bikarbonat, natrijev karbonat, natrijev sulfat, natrijev stearat, natrijev askorbat, natrijev benzoat, natrijev bifosfat, natrijev fosfat, natrijev bisulfit, natrijev citrat, natrijev borat, natrijev glukonat, natrijev metasilikat, te natrijev laktat, pri čemu proizvoljno natrijeva sol je natrijev klorid, ili pri čemu natrijeva sol je natrijev laktat, natrijev citrat, ili natrijev sulfat.
11. Farmaceutska formulacija prema zahtjevu 1-6, naznačena time da farmaceutska formulacija je suha praškasta formulacija.
12. Farmaceutska formulacija prema zahtjevu 11, naznačena time da kalcijeva sol je prisutna u količini od 19.5% do 90% (tež./tež.).
13. Farmaceutska formulacija prema zahtjevu 11 ili 12, naznačena time da kalcijeva sol je odabrana iz skupine koja sadrži kalcijev klorid, kalcijev karbonat, kalcijev acetat, kalcijev fosfat, kalcijev alginat, kalcijev stearat, kalcijev sorbat, kalcijev sulfat, kalcijev glukonat, kalcijev laktat i kalcijev citrat, pri čemu proizvoljno kalcijeva sol je kalcijev laktat, kalcijev citrat, kalcijev sulfat ili kalcijev klorid.
14. Farmaceutska formulacija prema bilo kojem od zahtjeva 11-13, naznačena time da natrijeva sol je odabrana iz skupine koja sadrži natrijev klorid, natrijev acetat, natrijev bikarbonat, natrijev karbonat, natrijev sulfat, natrijev stearat, natrijev askorbat, natrijev benzoat, natrijev bifosfat, natrijev fosfat, natrijev bisulfit, natrijev citrat, natrijev borat, natrijev glukonat, natrijev metasilikat, te natrijev laktat, pri čemu proizvoljno natrijeva sol je natrijev klorid, ili pri čemu natrijeva sol je natrijev laktat, natrijev citrat, ili natrijev sulfat.
15. Farmaceutska formulacija prema bilo kojem od zahtjeva 1-14, naznačena time da farmaceutska formulacija je formulirana da donosi Ca+2 dozu od 0.001 mg/kg tjelesne težine/dozi do 10 mg/kg tjelesne težine/dozi u dišni sustav, i/ili nadalje sadrži pomoćnu tvar, pri čemu je proizvoljno pomoćna tvar odabrana iz skupine koja sadrži laktozu, glicin, alanin, leucin, izoleucin, trehalozu, dipalmitoilfosfosfatidilkolin (DPPC), difosfatidil glicerol (DPPG), 1,2-Dipalmitoil-sn-glicero-3-fosfo-L-serin (DPPS), 1,2-Dipalmitoil-sn-glicero-3-fosfokolin (DSPC), 1,2-Distearoil-sn-glicero-3-fosfoetanolamin (DSPE), 1-palmitoil-2-oleoilfosfatidilkolin (POPC), polioksietilen-9-lauril eter, sorbitan trioleat (Span 85), glikokolat, surfaktin, tiloksapol, natrijev fosfat, dekstran, dekstrin, manitol, maltodekstrin, humani serumski albumin, rekombinantni humani serumski albumin, i biorazgradive polimere, pri čemu proizvoljno pomoćna tvar je leucin, maltodekstrin, ili manitol.
16. Farmaceutska formulacija prema bilo kojem od zahtjeva 1-15, naznačena time da farmaceutska formulacija je formulacija sa jediničnim doziranjem.
17. Učinkovita količina farmaceutske formulacije prema bilo kojem od zahtjeva 1-16 naznačena time da je za uporabu za liječenje infekcije dišnih puteva kod pojedinca koji ima infekciju dišnih puteva, pokazuje simptome infekcije dišnih puteva, ili ima rizik za dobivanje infekcije dišnih puteva.
18. Učinkovita količina farmaceutske formulacije prema bilo kojem od zahtjeva 1-16 naznačena time da je za uporabu za smanjivanje širenja infekcije dišnih puteva kod pojedinca koji ima infekciju dišnih puteva, pokazuje simptome infekcije dišnih puteva, ili ima rizik za dobivanje infekcije dišnih puteva.
19. Farmaceutska formulacija prema zahtjevu 17 ili 18, naznačena time da infekcija dišnih puteva je gripa, proizvoljno (i) gdje je gripa uzrokovana sa virusom gripe A ili virusom gripe B, ili (ii) gdje je infekcija dišnih puteva uzrokovana sa humani parainfluenza virusom, pri čemu proizvoljno humani parainfluenza virus je humani parainfluenza virus 3 (hPIV-3), ili (iii) gdje je infekcija dišnih puteva uzrokovana sa rinovirusom, ili (iv) gdje je infekcija dišnih puteva uzrokovana sa respiratornim sincitijalnim virusom (RSV), ili (v) gdje je infekcija dišnih puteva je upala pluća, pri čemu proizvoljno upala pluća je bakterijska upala pluća, pri čemu proizvoljno bakterijska upala pluća je uzrokovana sa S. pneumoniae, ili (vi) gdje je infekcija dišnih puteva je bakterijska infekcija, pri čemu proizvoljno bakterijska infekcija je uzrokovana sa bakterijom odabranom iz skupine koja sadrži Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus agalactiae, Streptococcus pyogenes, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosa, Moraxella catarrhalis, Chlamydophila pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, Serratia marcescens, Burkholderia cepacia, Burkholderia pseudomallei, Bacillus anthracis, Bacillus cereus, Bordatella pertussis, Stenotrophomonas maltophilia, bakterija iz obitelji citrobacter, bakterija iz obitelji ecinetobacter, te Mycobacterium tuberculosis.
20. Učinkovita količina farmaceutske formulacije prema bilo kojem od zahtjeva 1-16 naznačena time da je za uporabu za liječenje plućne bolesti kod pojedinca koji ima plućnu bolest, pokazuje simptome plućne bolesti, ili je podložan dobivanju plućne bolesti.
21. Učinkovita količina farmaceutske formulacije prema bilo kojem od zahtjeva 1-16 naznačena time da je za uporabu kod liječenja akutne egzacerbacije plućne bolesti kod pojedinca koji ima akutnu egzacerbaciju plućne bolesti, pokazuje simptome akutne egzacerbacije plućne bolesti, ili je podložan dobivanju akutne egzacerbacije plućne bolesti.
22. Farmaceutska formulacija prema zahtjevima 20 ili 21, naznačena time da plućna bolest je astma, preosjetljivost dišnih putova, alergijski rinitis, sezonska alergija, bronhiektazija, kronični bronhitis, emfizem, kronična opstruktivna plućna bolest ili cistična fibroza.
23. Farmaceutska formulacija prema zahtjevu 21, naznačena time da je akutna egzacerbacija kronične plućne bolesti uzrokovana sa virusnom infekcijom, bakterijskom infekcijom, gljivičnom infekcijom, parazitskom infekcijom, alergenom iz okoliša ili iritirajućim sredstvom iz okoliša.
24. Farmaceutska formulacija prema bilo kojem od zahtjeva 1-23, naznačena time da nadalje sadrži dodatno ljekovito sredstvo.
HR20120262T 2009-03-26 2012-03-22 Farmaceutske formulacije i postupci za liječenje infekcija dišnih puteva HRP20120262T1 (hr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16376709P 2009-03-26 2009-03-26
US16376309P 2009-03-26 2009-03-26
US16377209P 2009-03-26 2009-03-26
US25576409P 2009-10-28 2009-10-28
US29809210P 2010-01-25 2010-01-25
US30581910P 2010-02-18 2010-02-18
PCT/US2010/028906 WO2010111644A1 (en) 2009-03-26 2010-03-26 Pharmaceutical formulations and methods for treating respiratory tract infections

Publications (1)

Publication Number Publication Date
HRP20120262T1 true HRP20120262T1 (hr) 2012-04-30

Family

ID=42562904

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120262T HRP20120262T1 (hr) 2009-03-26 2012-03-22 Farmaceutske formulacije i postupci za liječenje infekcija dišnih puteva

Country Status (20)

Country Link
US (2) US20120107414A1 (hr)
EP (1) EP2315580B1 (hr)
JP (1) JP2012522011A (hr)
KR (1) KR20120002981A (hr)
CN (1) CN102448440A (hr)
AT (1) ATE538774T1 (hr)
AU (1) AU2010229724B2 (hr)
BR (1) BRPI1014783A2 (hr)
CA (1) CA2754680A1 (hr)
DK (1) DK2315580T3 (hr)
ES (1) ES2379775T3 (hr)
HK (1) HK1156847A1 (hr)
HR (1) HRP20120262T1 (hr)
IL (1) IL215275A0 (hr)
MX (1) MX2011009959A (hr)
PL (1) PL2315580T3 (hr)
PT (1) PT2315580E (hr)
RS (1) RS52239B (hr)
RU (1) RU2011137961A (hr)
WO (1) WO2010111644A1 (hr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
US20120083531A1 (en) * 2009-03-26 2012-04-05 Clarke Robert W Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
EP3184099A1 (en) 2009-03-26 2017-06-28 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
WO2012030664A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
US20130164338A1 (en) 2010-08-30 2013-06-27 Pulmatrix, Inc. Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
WO2012050945A1 (en) 2010-09-29 2012-04-19 Pulmatrix, Inc. Cationic dry powders
EP2621484A1 (en) 2010-09-29 2013-08-07 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
AU2012267938B2 (en) 2011-06-07 2017-05-04 Parion Sciences, Inc. Methods of treatment
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
WO2013052844A1 (en) 2011-10-07 2013-04-11 Pulmatrix, Inc. Methods for treating and diagnosing respiratory tract infections
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
US9636360B2 (en) * 2012-09-18 2017-05-02 pH Science Holdings, Inc Method and composition for treating gastro-esophageal disorders
AU2014248455B2 (en) 2013-04-01 2018-12-06 Pulmatrix Operating Company, Inc. Tiotropium dry powders
KR101658048B1 (ko) 2014-06-25 2016-09-20 한국생명공학연구원 포스파티딜콜린 합성경로 관여 물질을 포함하는 항바이러스용 조성물
CN107106641B (zh) 2014-10-31 2021-12-21 葛兰素史密斯克莱知识产权发展有限公司 粉末制剂
US10046007B2 (en) 2015-06-24 2018-08-14 Prescient Pharma, Llc Compositions and methods for treatment of short telomere disorders
US11141545B2 (en) * 2016-12-01 2021-10-12 Mark L. Anderson, Llc Sprayer technology
FR3081325B1 (fr) * 2018-05-23 2020-10-09 Univ Claude Bernard Lyon Diltiazem pour son utilisation dans le traitement des infections microbiennes
US20210079104A1 (en) * 2019-09-16 2021-03-18 The Regents Of The University Of California Methods and agents for treating infections
IT202000005026A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso inalatorio ad azione antivirale
WO2021245656A1 (en) * 2020-05-31 2021-12-09 Nicogen Ltd. Nicotine compositions for inhalation and anti-viral uses thereof
CN113827614A (zh) * 2020-06-24 2021-12-24 厦门大学 制备药用混合物的方法、所得药用混合物及其医药用途
US20220040227A1 (en) * 2020-08-10 2022-02-10 Reverspah Llc Method and composition for treating corona virus, influenza, and acute respiratory distress syndrome
CN111759851B (zh) * 2020-08-17 2021-01-26 广东盛普生命科技有限公司 单宁酸在制备抗冠状病毒的药物方面的应用
WO2022187702A1 (en) * 2021-03-05 2022-09-09 Philera New Zealand Prevention and treatment of coronavirus and related respiratory infections
CN114410745B (zh) * 2022-02-16 2023-05-02 长沙索科亚生物技术有限公司 粘性生物样本液化剂及其组合产品、试剂盒、扩增方法、检测方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4637815A (en) * 1985-08-06 1987-01-20 Lemole Gerald M Irrigational hemostatic solution
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
US5466680A (en) * 1992-03-26 1995-11-14 Cytologics, Inc. Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
SK284948B6 (sk) * 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
CN1194062C (zh) * 2003-04-04 2005-03-23 王泽斌 一种融雪融冰组合物及其制备方法和应用
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US20060073173A1 (en) * 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
US20070053844A1 (en) 2005-05-18 2007-03-08 Pulmatrix Inc. Formulations for alteration of biophysical properties of mucosal lining
US20120083531A1 (en) * 2009-03-26 2012-04-05 Clarke Robert W Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
CA2754677A1 (en) * 2009-03-26 2010-09-30 Pulmatrix, Inc. Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis

Also Published As

Publication number Publication date
DK2315580T3 (da) 2012-04-10
ATE538774T1 (de) 2012-01-15
BRPI1014783A2 (pt) 2018-06-12
JP2012522011A (ja) 2012-09-20
KR20120002981A (ko) 2012-01-09
IL215275A0 (en) 2011-11-30
MX2011009959A (es) 2012-01-27
US20140134251A1 (en) 2014-05-15
AU2010229724A1 (en) 2011-10-06
RS52239B (en) 2012-10-31
EP2315580B1 (en) 2011-12-28
PL2315580T3 (pl) 2012-05-31
PT2315580E (pt) 2012-03-28
HK1156847A1 (en) 2012-06-22
CA2754680A1 (en) 2010-09-30
AU2010229724B2 (en) 2014-07-17
US20120107414A1 (en) 2012-05-03
WO2010111644A1 (en) 2010-09-30
CN102448440A (zh) 2012-05-09
RU2011137961A (ru) 2013-05-10
EP2315580A1 (en) 2011-05-04
ES2379775T3 (es) 2012-05-03

Similar Documents

Publication Publication Date Title
HRP20120262T1 (hr) Farmaceutske formulacije i postupci za liječenje infekcija dišnih puteva
JP2012522011A5 (hr)
US20120058198A1 (en) Methods for treating and preventing pneumonia and ventilator-associated tracheobronchitis
JP2013536845A5 (hr)
IL256360A (en) Dry powders of a single metal cation for inhalation
US9233158B2 (en) Dry powder formulations and methods for treating pulmonary diseases
Velkov et al. Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead
Peltola et al. Respiratory viruses predisposing to bacterial infections: role of neuraminidase
WO2010111650A2 (en) Calcium citrate and calcium lactate formulations for alteration of biophysical properties of mucosal lining
SI1991201T1 (en) NEBULISED ANTIBIOTICS FOR INHALATION THERAPY
CA2754670A1 (en) Anti-influenza formulations and methods
US20130164338A1 (en) Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
JP2013503907A5 (hr)
JP2005535581A5 (hr)
KR20160127712A (ko) 다제내성 결핵 치료를 위한 흡입 에어로졸 면역화학요법
ES2437690B1 (es) Formulaciones inhalatorias en forma de soluciones o de polvos secos, para la eliminación de las secreciones mucosas del aparato respiratorio
US20110027315A1 (en) Protein cages and their uses
Chen et al. Ibuprofen Displays Synergistic Antibacterial Activity with Standard-of-Care Antibiotics Against Pseudomonas Aeruginosa
WO2022061010A1 (en) Antiviral oral composition, method of making the oral composition and oral hygiene method
AU2012258353A1 (en) Formulations for alteration of biophysical properties of mucosal lining
AR054219A1 (es) Formulacion de lisinato de aztreonam inhalable para el tratamiento y la prevencion de infecciones pulmonares bacteriales